• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Our Bureau

MUMBAI, March.20

RANBAXY Laboratories was on a high today after the company received a crucial nod from the USFDA (United States Food and Drug Administration) for one of its drugs.

Today, the stock ended higher by 5.81 per cent at Rs 617.30 with 3.77 lakh shares being traded on the BSE. On the NSE, it rose by 5.39 per cent to close at Rs 615.40 with 9 lakh shares changing hands. Of the traded shares, 50.52 per cent was presented for delivery on the BSE and 61.66 per cent on the NSE.

Ranbaxy has received an approval to market oral suspension of Amoxicillin and Clavulanate Potassium for oral suspension, 200 mg/28.5 mg (base)/5 ml and 400 mg/57 mg (base)/5 ml. The drug, which has passed the bio-equivalence tests in the US, is therapeutically equivalent to GlaxoSmithKline`s Augmentin for oral suspension. Augmentin has combined sales of $1.2 billion, with total sales of $272 million in the suspension market.

Amoxicillin and Clavulanate Potassium for oral suspension is indicated for the treatment of infections caused by susceptible strains of the designated organisms in the conditions such as `lower respiratory tract infections, Otitis Media, sinusitis, skin and skin structure infections, and urinary tract infections'.

The outbreak of war in the Gulf region is also expected to help the pharma industry in India, particularly Ranbaxy. Says an analyst from a domestic brokerage firm, "anti-infectives will be in great demand during and after the war and Ranbaxy with an established marketing set up in the US could be a huge beneficiary in exporting these drugs."

Article E-Mail :: Comment :: Syndication

Stories in this Section
Bull onslaught

Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line